Vasoactive Peptide Pharmacology

Correct Answer

C — Both V1 and V2 receptors

Rationale

Arginine vasopressin acts as an agonist at both V1 and V2 receptor subtypes. V1 receptors are located on vascular smooth muscle cells and mediate vasoconstriction, raising systemic vascular resistance. V2 receptors are located on the principal cells of the renal collecting duct and mediate water reabsorption through aquaporin-2 channel insertion. This dual receptor activity classifies vasopressin as a non-selective V1 and V2 agonist, which distinguishes it pharmacologically from desmopressin, a synthetic analog classified as a selective V2 agonist with minimal V1 activity. The AT1 receptor is an angiotensin II receptor, not a vasopressin receptor subtype.

Correct Answer

A — Selective V2 receptor antagonist

Rationale

Tolvaptan is classified as a selective V2 receptor antagonist. By blocking only the V2 receptor in the renal collecting duct, tolvaptan prevents vasopressin-driven aquaporin-2 insertion and promotes free water excretion without sodium loss — a process called aquaresis. Because tolvaptan does not block V1 receptors, it does not produce the vasodilation seen with conivaptan, which is a dual V1 and V2 antagonist. Tolvaptan is an antagonist, not an agonist; desmopressin is the selective V2 agonist in this drug set.

Correct Answer

B — Dual V1 and V2 receptor antagonist

Rationale

Conivaptan is classified as a dual V1 and V2 receptor antagonist. It is available only as an intravenous formulation for in-hospital use, distinguishing it from tolvaptan, which is an oral selective V2 antagonist. The V1 blockade component of conivaptan produces vasodilation, which limits its use in patients who are already hypotensive. Like tolvaptan, the V2 blockade component produces aquaresis — free water excretion without sodium loss. The dual receptor profile is the key classification distinction between conivaptan and tolvaptan within the vaptan class.

Correct Answer

D — Synthetic vasopressin analog classified as a selective V2 receptor agonist

Rationale

Desmopressin is a synthetic analog of vasopressin modified to be highly selective for the V2 receptor with minimal V1 activity. This selectivity eliminates the vasoconstrictor effects of native vasopressin, making desmopressin safe for long-term clinical use. As a V2 agonist, desmopressin activates collecting duct aquaporin-2 water channels — the same receptor and mechanism as endogenous vasopressin, but without the V1-mediated vasoconstriction. Tolvaptan and conivaptan are V2 receptor antagonists, not agonists. No approved drug is a selective V1 agonist for antidiuretic use.

Correct Answer

A — Oral selective V2 receptor antagonist

Rationale

Tolvaptan is classified as an oral selective V2 receptor antagonist. This two-part classification distinguishes it from conivaptan on both dimensions: conivaptan is intravenous rather than oral, and blocks both V1 and V2 receptors rather than V2 alone. Tolvaptan's oral availability allows outpatient use in principle, though hospital initiation is required due to the risk of overcorrection of hyponatremia. Option D describes conivaptan precisely.

Correct Answer

C — Aquaresis — free water excretion without sodium loss

Rationale

Vaptans are classified as agents that produce aquaresis — excretion of free water without concomitant sodium loss. This distinguishes them from loop diuretics and thiazides, which cause loss of both water and electrolytes (diuresis) and can worsen or unpredictably alter plasma sodium. By selectively removing free water through V2 receptor blockade and prevention of aquaporin-2 insertion, vaptans raise plasma sodium in hyponatremia caused by free water excess, such as the syndrome of inappropriate antidiuretic hormone secretion. The term aquaresis is the pharmacological class label that defines this drug group's mechanism of fluid removal.

Correct Answer

B — V2 receptor activation triggers insertion of aquaporin-2 water channels into the luminal membrane of collecting duct principal cells, dramatically increasing water permeability

Rationale

V2 receptors on collecting duct principal cells are coupled to Gs proteins, activating adenylyl cyclase and raising cyclic AMP. Elevated cyclic AMP activates protein kinase A, which phosphorylates aquaporin-2 water channels stored in intracellular vesicles, triggering their fusion with and insertion into the luminal membrane. With aquaporin-2 channels in place, the luminal membrane becomes highly permeable to water, allowing water to move osmotically from the tubular lumen into the hypertonic medullary interstitium, producing concentrated urine. This aquaporin-2 insertion mechanism is the molecular basis for both the antidiuretic effect of vasopressin and desmopressin, and for the aquaretic effect of vaptans when they block this process.

Correct Answer

D — Tolvaptan blocks V2 receptors in the collecting duct, preventing aquaporin-2 insertion and allowing free water to be excreted without sodium loss, raising plasma sodium concentration

Rationale

In hyponatremia caused by vasopressin excess — such as the syndrome of inappropriate antidiuretic hormone secretion — continued V2 receptor activation drives aquaporin-2 insertion and water retention despite low plasma osmolality. Tolvaptan competitively blocks the V2 receptor, preventing vasopressin from triggering aquaporin-2 insertion. Without aquaporin-2 channels in the luminal membrane, the collecting duct remains impermeable to water, and free water passes into the urine — aquaresis. Because sodium is not lost in this process, plasma sodium concentration rises as the excess free water is cleared. Unlike loop diuretics, which cause loss of both water and electrolytes, tolvaptan selectively removes free water, making it mechanistically suited to correct dilutional hyponatremia.

Correct Answer

A — Vasopressin is secreted despite low plasma osmolality, driving continued water reabsorption via aquaporin-2; plasma sodium falls because water is retained in excess, not because sodium is lost, and total body sodium remains normal producing euvolemia

Rationale

Normally, vasopressin secretion is suppressed when plasma osmolality falls, allowing the kidney to excrete dilute urine and correct any free water excess. In the syndrome of inappropriate antidiuretic hormone secretion, vasopressin continues to be secreted despite low plasma osmolality, driving sustained aquaporin-2 insertion and water reabsorption. Because water distributes throughout total body water rather than remaining in the vascular space alone, there is no volume overload — patients are euvolemic. The hyponatremia is dilutional: plasma sodium falls because retained water dilutes it, not because sodium is being lost. This euvolemic pattern is the key clinical feature distinguishing the syndrome from hyponatremia caused by heart failure or cirrhosis, where patients are hypervolemic, or from hyponatremia caused by adrenal insufficiency, where patients are hypovolemic.

Correct Answer

C — In chronic hyponatremia the brain adapts by losing intracellular osmoles; rapid correction raises extracellular osmolality faster than brain cells can readapt, causing osmotic water loss from neurons and demyelination; the maximum safe rate is 8 to 10 mEq/L per 24 hours

Rationale

In chronic hyponatremia, brain cells adapt to the low extracellular osmolality by extruding intracellular osmoles — organic molecules that normally maintain cellular volume. When sodium is corrected too rapidly, extracellular osmolality rises faster than brain cells can re-accumulate these osmoles. Water moves osmotically out of neurons, causing cellular shrinkage and demyelination of central pontine and extrapontine white matter. The result is osmotic demyelination syndrome — potentially producing locked-in syndrome or death. The maximum safe correction rate is 8 to 10 mEq/L per 24 hours in most patients, and no more than 18 mEq/L in the first 48 hours. Acute hyponatremia developing within 48 hours can be corrected more rapidly because the brain has not had time to adapt osmotically.

Correct Answer

B — In central diabetes insipidus, the V2 receptor is intact and desmopressin restores aquaporin-2 insertion; in nephrogenic diabetes insipidus, the V2 receptor is absent or the aquaporin-2 system is resistant, so adding a V2 agonist cannot overcome the downstream defect

Rationale

Central diabetes insipidus results from deficient vasopressin production in the hypothalamus. The collecting duct V2 receptor and aquaporin-2 system are structurally intact; they simply lack adequate hormonal stimulation. Desmopressin supplies exogenous V2 receptor activation, restoring aquaporin-2 insertion and urine concentration. Nephrogenic diabetes insipidus results from renal resistance to vasopressin — the V2 receptor itself is absent in the X-linked inherited form, blocked by drugs such as lithium or demeclocycline in acquired forms, or the downstream aquaporin-2 system is dysfunctional. In this setting, adding more V2 receptor agonist cannot restore function because the target receptor or effector system is unavailable. Treatment of nephrogenic diabetes insipidus therefore does not use desmopressin but rather thiazide diuretics and dietary sodium restriction to create mild volume contraction that indirectly reduces urine output.

Correct Answer

D — Desmopressin activates V2 receptors on vascular endothelial cells, triggering exocytosis of Weibel-Palade bodies and releasing stored von Willebrand factor and factor VIII into the circulation within 30 to 60 minutes

Rationale

The hemostatic mechanism of desmopressin operates through V2 receptors on vascular endothelial cells — the same receptor subtype responsible for its antidiuretic effect in the collecting duct, but in a different tissue location and producing a different response. V2 receptor activation on endothelial cells triggers exocytosis of Weibel-Palade bodies, specialized storage organelles that contain pre-formed von Willebrand factor and factor VIII. These clotting factors are rapidly released into the circulation, typically within 30 to 60 minutes of administration, producing a transient surge sufficient to cover minor surgical procedures or dental extractions. This mechanism explains why desmopressin works in mild hemophilia A (factor VIII activity above 5 to 10 percent) and type 1 von Willebrand disease but not in severe hemophilia A — where baseline factor VIII is too low for a relative increase to achieve hemostasis — or in type 2B von Willebrand disease, where released abnormal von Willebrand factor can worsen thrombocytopenia.

Correct Answer

A — V1 receptor blockade removes vasopressin-mediated vasoconstriction on systemic vascular smooth muscle, producing vasodilation that can worsen hypotension in patients who are already hypotensive

Rationale

V1 receptors on vascular smooth muscle mediate vasopressin-driven vasoconstriction, contributing to systemic vascular resistance. When conivaptan blocks V1 receptors, this vasoconstrictive tone is removed, producing systemic vasodilation. In a patient with hyponatremia who is also hypotensive — such as one with cirrhosis or sepsis-associated hyponatremia — this vasodilation can cause clinically significant further drops in blood pressure. Tolvaptan, which selectively blocks only the V2 receptor, does not produce V1-mediated vasodilation and is therefore preferred in patients with borderline hemodynamics. V1 receptors are located on vascular smooth muscle, not in the kidney tubule, pituitary, or collecting duct aquaporin-2 system.

Correct Answer

C — Based on the TEMPO 3:4 trial, tolvaptan carries a black box warning for serious liver injury; it is contraindicated in liver disease, must not be used for more than 30 days, and must be initiated in a hospital setting

Rationale

Serious liver injury was identified in the TEMPO 3:4 trial, which evaluated tolvaptan at high doses for extended periods in autosomal dominant polycystic kidney disease. This evidence led to a black box warning for hepatotoxicity. Three prescribing restrictions were imposed: tolvaptan is contraindicated in patients with liver disease including cirrhosis, which also eliminated its previous approval for cirrhosis-associated hyponatremia in some regions; treatment duration is limited to 30 days; and initiation must occur in a hospital setting where sodium levels can be monitored to prevent dangerous overcorrection. Tolvaptan is also a cytochrome P450 3A4 substrate and inhibitor, with interactions requiring dose adjustment, but the hepatotoxicity risk is intrinsic to the drug and not solely interaction-dependent.

Correct Answer

B — V2 receptor antagonists, which block vasopressin-driven water reabsorption and promote free water excretion without sodium loss

Rationale

This patient has the syndrome of inappropriate antidiuretic hormone secretion from ectopic vasopressin production by small cell lung cancer — the laboratory pattern of euvolemic hyponatremia with inappropriately concentrated urine and urinary sodium wasting confirms this. The mechanism is continued vasopressin-driven aquaporin-2 insertion in the collecting duct despite low plasma osmolality, retaining free water and diluting sodium. V2 receptor antagonists such as tolvaptan or conivaptan directly target this mechanism by blocking V2 receptors and preventing aquaporin-2 insertion, allowing free water to be excreted as aquaresis and raising plasma sodium. Loop diuretics remove both water and electrolytes and can unpredictably worsen hyponatremia. Aldosterone antagonists and angiotensin-converting enzyme inhibitors do not address the vasopressin-driven free water retention that is the primary mechanism here.

Correct Answer

D — Desmopressin supplies exogenous V2 receptor activation and restores aquaporin-2 insertion because the collecting duct receptor and effector system are intact; in nephrogenic disease the V2 receptor is absent or the downstream effector system is resistant, so adding a V2 agonist cannot overcome the defect

Rationale

Central diabetes insipidus results from deficient vasopressin production — the collecting duct V2 receptor and aquaporin-2 apparatus are structurally intact and simply lack hormonal stimulation. Desmopressin, a selective V2 agonist, supplies that stimulation and restores urine concentration. In nephrogenic diabetes insipidus, the problem lies at or downstream of the V2 receptor: the receptor is absent in the X-linked hereditary form, blocked by lithium or demeclocycline in acquired forms, or the aquaporin-2 system itself is dysfunctional. Providing more V2 agonist in this setting cannot restore function because the receptor or its effector machinery is unavailable. This mechanistic distinction — intact receptor in central disease, absent or resistant receptor in nephrogenic disease — determines the pharmacological approach: desmopressin works in central, thiazide diuretics and sodium restriction in nephrogenic.

Correct Answer

A — The sodium was corrected by 14 mEq/L in 24 hours, exceeding the safe limit; the brain had adapted to chronic hyponatremia by losing intracellular osmoles, and the rapid rise in extracellular osmolality caused osmotic water loss from neurons, demyelinating central pontine and extrapontine white matter

Rationale

In chronic hyponatremia, brain cells adapt by extruding intracellular osmoles to maintain volume equilibrium in the hypotonic environment. The sodium here was corrected by 14 mEq/L in 24 hours — well above the safe maximum of 8 to 10 mEq/L per 24 hours. When extracellular osmolality rises this rapidly, brain cells cannot re-accumulate osmoles fast enough to maintain volume equilibrium. Water moves osmotically out of neurons, causing cellular shrinkage and demyelination of the central pons and surrounding structures — osmotic demyelination syndrome. This patient's risk was compounded by alcoholism and malnutrition, which are additional risk factors for osmotic demyelination. The neurological injury is largely irreversible. If the sodium had risen faster than intended, the correct intervention is administration of hypotonic fluids or desmopressin to slow or partially reverse the correction.

Correct Answer

C — Desmopressin activates V2 receptors on vascular endothelial cells, triggering Weibel-Palade body exocytosis and releasing stored von Willebrand factor and factor VIII; repeated doses cause tachyphylaxis as endothelial Weibel-Palade body stores are depleted and cannot be rapidly replenished

Rationale

Desmopressin's hemostatic effect operates through V2 receptors on vascular endothelial cells — the same receptor subtype targeted in the collecting duct for antidiuresis, but producing a different cellular response. V2 activation triggers exocytosis of Weibel-Palade bodies, specialized endothelial storage organelles containing pre-formed von Willebrand factor and factor VIII. These clotting factors are released into the circulation within 30 to 60 minutes, producing a transient surge that raises factor VIII activity sufficiently to permit hemostasis during minor procedures in patients with mild hemophilia A. The limitation of this mechanism is its reliance on pre-formed stores: Weibel-Palade bodies require time to replenish after exocytosis, and repeated desmopressin doses within 24 to 48 hours exhaust these stores, producing tachyphylaxis with diminishing hemostatic responses. This is distinct from hepatic factor synthesis, which is not the mechanism of desmopressin's hemostatic action.